Overview

Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Safety and tolerability. Quality of life (EQ-5D, ACQLI) and health economic impact (health resource utilisation, living and employment status) assessments, will not be performed at the centers in the united kingdom (UK)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim